Pharmaceuticals & Therapeutics

A global partnership aims to bring Atla-cel, a next-gen CAR-T therapy with low neurotoxicity, to children with leukaemia, potentially revolutionizing treatment.

Velo Med Spa introduces a revolutionary non-surgical body contouring solution using donor-derived tissue, promising natural results without the knife.

A novel drug combination shows promising early results for a deadly ovarian cancer, potentially expanding the benefit of immunotherapy to more patients.

A new alliance aims to deliver nine vital rare disease therapies to Africa, tackling one of global health's most profound access challenges.

ANI Pharmaceuticals launches a generic version of Carbatrol, aiming for a slice of a $65M market and promising improved patient access for chronic conditions.

With youth melanoma a growing concern, a new curriculum gives teens free, classroom-ready tools to build lifelong sun safety habits and reduce their risk.

With a new CEO from rival InMode and backing from a global powerhouse, Boston Aesthetics is poised to shake up the competitive medical aesthetics industry.

Backed by Maria Sharapova, new startup Amulet launches a science-first supplement aiming to optimize women's performance throughout their entire cycle.

A landmark study reveals 100% tumor control with a personalized radiation therapy, offering profound new hope for patients with inoperable liver cancer.

With the key hire of a new commercial VP, Grey Wolf Animal Health aims to unlock synergies between its booming pharmacy and animal health divisions.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

A new partnership introduces PBSerum®, a biologically inspired enzyme treatment, aiming to redefine skin quality in the multi-billion dollar aesthetics market.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

A group known for challenging pandemic rules will now advise on US vaccine policy. Can it rebuild trust, or will it deepen the medical divide?

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

My Derma Dream's MyoGlow promises a surgery-free arm lift. We investigate the science, the marketing, and the guarantee fine print consumers must see.

A new company is selling franchises to doctors and pharmacists, promising to cut out insurers and restore local care. But can this bold model survive the system?